Trimedyne Inc (TMED) 0.1012 $TMED
TRIMEDYNE Reports Its Financial Results for The Quarter And Nine Months Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 8:16AM CDT
IRVINE, CA, United States / ACCESSWIRE / Aug 14, 2014 / TRIMEDYNE, INC. (OTCQB: TMED"
today reported its financial results for the quarter and nine-month period ended June 30, 2014.
Trimedyne Reports Its Financial Results for the Quarter Ended December 31, 2013
Marketwire - Wed Feb 19, 8:15AM CST
TRIMEDYNE, INC. (OTCQB: TMED) (OTCBB: TMED) today reported its financial results for the first quarter of its fiscal year.
Trimedyne Reports Financial Results for the Quarter and Fiscal Year Ended September 30, 2013
Marketwire - Wed Jan 15, 7:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED) (OTCQB: TMED) reported revenues of $5,989,000 for the fiscal year ended September 30, 2012, a 1.5% decrease from revenues of $6,080,000 for the prior fiscal year. The decrease was primarily due to the decrease in domestic Laser sales combined with the delaying of shipments of Fibers, Needles and Switch Tips resulting from the relocation to our new manufacturing facility in Irvine, California.
Global Medical Laser Systems Market Report 2013-2018: Global Aesthetics Laser Market Poised to Grow
M2 - Thu Sep 05, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/np483b/medical_laser#summary) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services. The report profiles 139 companies including many key and niche players such as: - AngioDynamics Inc. - Bausch & Lomb Incorporated - BIOLASE Inc. - Biolitec AG - Cardiogenesis Corporation - Carl Zeiss Meditec AG - Coherent Inc. - Cutera Inc - Cynosure Inc. - Palomar Medical Technologies Inc. - Dornier Medtech GmbH - Ellex Medical Lasers Limited - IRIDEX Corporation - Lumenis Ltd - Lynton Lasers Ltd - Nidek Co Ltd. - Novartis AG - PhotoMedex Inc. - Radiancy Inc. - Spectranetics Corporation - Syneron Medical Ltd. - Candela Corporation - Topcon Corporation - Trimedyne Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 139 (including Divisions/Subsidiaries - 175) - The United States (87) - Canada (3) - Japan (6) - Europe (64) - - France (6) - - Germany (28) - - The United Kingdom (6) - - Italy (
- - Spain (1) - - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (12) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/np...er#summary
Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2013
ACCESSWIRE - Thu Aug 22, 8:07AM CDT
Irvine, CA, August 22, 2013 - (Accesswire) - TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and nine months ended June 30, 2013.
Trimedyne Reports Its Financial Results for the Quarter and Six Months Ended March 31, 2013
Marketwire - Thu Jun 20, 8:01AM CDT
TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and six month period ended March 31, 2013.
Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
PR Newswire - Fri Feb 01, 8:00AM CST
TRIMEDYNE, INC. (OTCBB "TMED" reported revenues of $6,080,000 for the fiscal year ended September 30, 2012, a 9% decrease from revenues of $6,656,000 for the prior fiscal year. The decrease in revenues was largely due to a decrease in sales of Lasers, partially offset by an increase in sales of Fibers, Needles and Tips.
John C. Chiu, M.D., Has Agreed to Be Medical Director and Chief Investigator of the Clinical Trials of Hyperdyne, Inc., a Subsidiary Being Created by Trimedyne
Marketwire - Mon Jan 07, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED), today announced that John C. Chiu, M.D., an internationally respected neurosurgeon who practices in Newbury Park, CA, has agreed to serve as Medical Director and Chief Investigator of the three (3) randomized, controlled clinical trials to be conducted, subject to receiving funding, by Orthodyne, Inc., ("Orthodyne" , a subsidiary being a organized by Trimedyne.
Professor Anthony J. Costello, M.D. Agrees to Conduct Pre-Clinical Testing and Lead the Clinical Trials in Asia and Southeast Asia of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Being Created by Trimedyne
Marketwire - Thu Dec 27, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED) today announced Professor Anthony J. Costello, M.D., Head of the Department of Urology of the Royal Melbourne Hospital of the University of Melbourne (Australia), will serve as Lead Investigator in Asia and Southeast Asia, subject to their receiving funding, of the three (3), 300 patient, randomized, controlled clinical trials of Urodyne, Inc. ("Urodyne" in the treatment of Benign Prostatic Hyperplasia or BPH (commonly called an enlarged prostate) and the treatment of Urinary Incontinence and Fecal Incontinence and, subject to their receiving funding, the two (2), 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" in the treatment of Uncontrolled Hypertension (high blood pressure not controllable by drugs) in Endoscopic and Percutaneous (balloon angioplasty-like) Procedures. He will select the medical centers to participate in the clinical trials in these areas of the world and train the physicians of the medical centers in the co
Graham M. Watson, M.D., Agrees to Serve as Lead Investigator of the Clinical Trials in Europe and Middle East of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Trimedyne Plans to Create
Marketwire - Fri Dec 21, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED), today announced Graham M. Watson, M.D., has agreed to serve as Lead Investigator in Europe and the Middle East, subject to receiving funding, of the three (3), 300 patient, randomized clinical trials of Urodyne, Inc. ("Urodyne" to treat Benign Prostatic Hyperplasia or BPH, commonly referred to as an "Enlarged Prostate," urinary incontinence and fecal incontinence in Endoscopic Procedures and, subject to receiving funding, the two (2) 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" to treat Hypertension not controllable by drugs, one in Endoscopic Procedures and the other in Percutaneous (angioplasty-like) Procedures.
Robert S. Cowles, III, M.D. Joins Urodyne, Inc. and Hyperdyne, Inc., Two Subsidiaries Trimedyne Plans to Organize, as Co-Chairman and Medical Director
Marketwire - Thu Dec 20, 8:01AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED) today announced that Robert S. Cowles, III, M.D. has agreed to serve as Co-Chairman with Dr. Marvin P. Loeb of the Boards of Directors and as Medical Director of Urodyne, Inc. ("Urodyne" and Hyperdyne, Inc. ("Hyperdyne" , two subsidiaries Trimedyne plans to organize. (See Trimedyne's Press Release of November 28, 2012).
Robert S. Cowles, III, M.D. Joins Trimedyne as Its Medical Director
Marketwire - Wed Dec 19, 8:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED), today announced that Robert S. Cowles, III, M.D. has agreed to serve as Medical Director of Trimedyne. He will review Trimedyne's new technologies and advise Trimedyne on the design of the clinical trials to be conducted, subject to receipt of funding, by the seven (7) subsidiaries Trimedyne plans to organize (See Trimedyne's Press Release dated November 28, 2012).
TRIMEDYNE Reports Its Financial Results for The Quarter And Nine Months Ended June 30, 2014
ACCESSWIRE - Thu Aug 14, 8:16AM CDT
IRVINE, CA, United States / ACCESSWIRE / Aug 14, 2014 / TRIMEDYNE, INC. (OTCQB: TMED"
today reported its financial results for the quarter and nine-month period ended June 30, 2014. Trimedyne Reports Its Financial Results for the Quarter Ended December 31, 2013
Marketwire - Wed Feb 19, 8:15AM CST
TRIMEDYNE, INC. (OTCQB: TMED) (OTCBB: TMED) today reported its financial results for the first quarter of its fiscal year.
Trimedyne Reports Financial Results for the Quarter and Fiscal Year Ended September 30, 2013
Marketwire - Wed Jan 15, 7:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED) (OTCQB: TMED) reported revenues of $5,989,000 for the fiscal year ended September 30, 2012, a 1.5% decrease from revenues of $6,080,000 for the prior fiscal year. The decrease was primarily due to the decrease in domestic Laser sales combined with the delaying of shipments of Fibers, Needles and Switch Tips resulting from the relocation to our new manufacturing facility in Irvine, California.
Global Medical Laser Systems Market Report 2013-2018: Global Aesthetics Laser Market Poised to Grow
M2 - Thu Sep 05, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/np483b/medical_laser#summary) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services. The report profiles 139 companies including many key and niche players such as: - AngioDynamics Inc. - Bausch & Lomb Incorporated - BIOLASE Inc. - Biolitec AG - Cardiogenesis Corporation - Carl Zeiss Meditec AG - Coherent Inc. - Cutera Inc - Cynosure Inc. - Palomar Medical Technologies Inc. - Dornier Medtech GmbH - Ellex Medical Lasers Limited - IRIDEX Corporation - Lumenis Ltd - Lynton Lasers Ltd - Nidek Co Ltd. - Novartis AG - PhotoMedex Inc. - Radiancy Inc. - Spectranetics Corporation - Syneron Medical Ltd. - Candela Corporation - Topcon Corporation - Trimedyne Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 139 (including Divisions/Subsidiaries - 175) - The United States (87) - Canada (3) - Japan (6) - Europe (64) - - France (6) - - Germany (28) - - The United Kingdom (6) - - Italy (
- - Spain (1) - - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (12) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/np...er#summary Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2013
ACCESSWIRE - Thu Aug 22, 8:07AM CDT
Irvine, CA, August 22, 2013 - (Accesswire) - TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and nine months ended June 30, 2013.
Trimedyne Reports Its Financial Results for the Quarter and Six Months Ended March 31, 2013
Marketwire - Thu Jun 20, 8:01AM CDT
TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and six month period ended March 31, 2013.
Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
PR Newswire - Fri Feb 01, 8:00AM CST
TRIMEDYNE, INC. (OTCBB "TMED"
reported revenues of $6,080,000 for the fiscal year ended September 30, 2012, a 9% decrease from revenues of $6,656,000 for the prior fiscal year. The decrease in revenues was largely due to a decrease in sales of Lasers, partially offset by an increase in sales of Fibers, Needles and Tips. John C. Chiu, M.D., Has Agreed to Be Medical Director and Chief Investigator of the Clinical Trials of Hyperdyne, Inc., a Subsidiary Being Created by Trimedyne
Marketwire - Mon Jan 07, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne"
(OTCBB: TMED), today announced that John C. Chiu, M.D., an internationally respected neurosurgeon who practices in Newbury Park, CA, has agreed to serve as Medical Director and Chief Investigator of the three (3) randomized, controlled clinical trials to be conducted, subject to receiving funding, by Orthodyne, Inc., ("Orthodyne" , a subsidiary being a organized by Trimedyne. Professor Anthony J. Costello, M.D. Agrees to Conduct Pre-Clinical Testing and Lead the Clinical Trials in Asia and Southeast Asia of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Being Created by Trimedyne
Marketwire - Thu Dec 27, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne"
(OTCBB: TMED) today announced Professor Anthony J. Costello, M.D., Head of the Department of Urology of the Royal Melbourne Hospital of the University of Melbourne (Australia), will serve as Lead Investigator in Asia and Southeast Asia, subject to their receiving funding, of the three (3), 300 patient, randomized, controlled clinical trials of Urodyne, Inc. ("Urodyne" in the treatment of Benign Prostatic Hyperplasia or BPH (commonly called an enlarged prostate) and the treatment of Urinary Incontinence and Fecal Incontinence and, subject to their receiving funding, the two (2), 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" in the treatment of Uncontrolled Hypertension (high blood pressure not controllable by drugs) in Endoscopic and Percutaneous (balloon angioplasty-like) Procedures. He will select the medical centers to participate in the clinical trials in these areas of the world and train the physicians of the medical centers in the co Graham M. Watson, M.D., Agrees to Serve as Lead Investigator of the Clinical Trials in Europe and Middle East of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Trimedyne Plans to Create
Marketwire - Fri Dec 21, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne"
(OTCBB: TMED), today announced Graham M. Watson, M.D., has agreed to serve as Lead Investigator in Europe and the Middle East, subject to receiving funding, of the three (3), 300 patient, randomized clinical trials of Urodyne, Inc. ("Urodyne" to treat Benign Prostatic Hyperplasia or BPH, commonly referred to as an "Enlarged Prostate," urinary incontinence and fecal incontinence in Endoscopic Procedures and, subject to receiving funding, the two (2) 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" to treat Hypertension not controllable by drugs, one in Endoscopic Procedures and the other in Percutaneous (angioplasty-like) Procedures. Robert S. Cowles, III, M.D. Joins Urodyne, Inc. and Hyperdyne, Inc., Two Subsidiaries Trimedyne Plans to Organize, as Co-Chairman and Medical Director
Marketwire - Thu Dec 20, 8:01AM CST
TRIMEDYNE, INC. ("Trimedyne"
(OTCBB: TMED) today announced that Robert S. Cowles, III, M.D. has agreed to serve as Co-Chairman with Dr. Marvin P. Loeb of the Boards of Directors and as Medical Director of Urodyne, Inc. ("Urodyne" and Hyperdyne, Inc. ("Hyperdyne" , two subsidiaries Trimedyne plans to organize. (See Trimedyne's Press Release of November 28, 2012). Robert S. Cowles, III, M.D. Joins Trimedyne as Its Medical Director
Marketwire - Wed Dec 19, 8:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED), today announced that Robert S. Cowles, III, M.D. has agreed to serve as Medical Director of Trimedyne. He will review Trimedyne's new technologies and advise Trimedyne on the design of the clinical trials to be conducted, subject to receipt of funding, by the seven (7) subsidiaries Trimedyne plans to organize (See Trimedyne's Press Release dated November 28, 2012).
